Tirzepatide vs AOD-9604
A detailed side-by-side comparison of Tirzepatide and AOD-9604 covering dosing, storage, research findings, and practical usage.
Overview
Tirzepatide: A dual GIP and GLP-1 receptor agonist for weight management.
AOD-9604: A modified fragment of human growth hormone targeting fat metabolism.
Comparison Table
| Property | Tirzepatide | AOD-9604 |
|---|---|---|
| Category | GLP-1/GIP Agonist | Fat Loss |
| Typical Dose | 2500-15000 mcg | 250-500 mcg |
| Frequency | 1x per week | 1x daily |
| Half-Life | ~5 days | ~30 minutes |
| Timing | Same day each week, any time of day | Morning fasted |
Tirzepatide Research
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist FDA-approved for Type 2 diabetes (Mounjaro) and weight management (Zepbound). Unlike semaglutide which only targets GLP-1, tirzepatide activates both GIP and GLP-1 receptors, providing enhanced metabolic benefits. Clinical trials (SURMOUNT) showed unprecedented weight loss results, with participants losing up to 22.5% of body weight - more than any other approved medication. It improves insulin sensitivity, reduces appetite, and may have additional benefits for fatty liver disease. The dual mechanism appears to provide superior efficacy compared to GLP-1 agonists alone.
Tirzepatide Full Guide | AOD-9604 Full Guide | Dosage Calculator | Shop Peptides
For laboratory research use only. Not for human consumption.